Nuvectis Pharma Earnings Call Transcripts
Fiscal Year 2025
-
NXP900, a novel oral Src inhibitor, is advancing in a broad phase 1b program targeting major unmet needs in advanced solid tumors, especially non-small cell lung cancer. Early data show high Src inhibition and favorable tolerability, with multiple combination studies and data readouts expected in 2026.
-
Phase 1B study for NXP900 has begun, targeting genetically defined advanced cancers as both monotherapy and in combination with EGFR/ALK inhibitors. The program leverages a strong cash position, robust preclinical and clinical data, and aims for significant market and regulatory milestones.
-
Two oncology drug candidates are advancing: NXP 800 is in phase 1B with dose optimization ongoing, and NXP 900, a highly selective SRC inhibitor, is nearing phase 1B with strong early data. Key clinical updates and potential expansion into larger markets are expected within two months.
Fiscal Year 2024
-
Two targeted oncology drugs are advancing in clinical trials, with NXP-800 showing early efficacy and safety improvements in ovarian cancer and NXP-900 demonstrating selectivity and promising preclinical synergy for resistant lung cancers. Financials remain strong, and the team has a proven track record.